Fibroblast growth factor receptor 4 polymorphism is associated with liver cirrhosis in hepatocarcinoma

Ming Jen Sheu, Ming Ju Hsieh, Whei Ling Chiang, Shun Fa Yang, Hsiang Lin Lee, Liang Ming Lee, Chao Bin Yeh

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Fibroblast growth factor receptor 4 (FGFR4) polymorphisms are positively correlated with tumor progression in numerous malignant tumors. However, the association between FGFR4 genetic variants and the risk of hepatocellular carcinoma (HCC) has not yet been determined. In this study, we investigated the potential associations of FGFR4 single nucleotide polymorphisms (SNPs) with HCC susceptibility and its clinicopathological characteristics. Methodology/Principal Findings: Four SNPs in FGFR4 (rs1966265, rs351855, rs2011077, and rs7708357) were analyzed among 884 participants, including 595 controls and 289 patients with HCC. The samples were further analyzed to clarify the associations between these gene polymorphisms and the risk of HCC, and the impact of these SNPs on the susceptibility and clinicopathological characteristics of HCC. After adjusting for other covariants, HCC patients who carrying at least one A genotype (GA and AA) at rs351855 were observed to have a higher risk of liver cirrhosis compared with those carrying the wild-type genotype (GG) (OR: 2.113, 95% CI: 1.188-3.831). Moreover, the patients with at least one A genotype were particularly showed a high level of alpha-fetoprotein (AFP). Conclusions: Our findings suggest that genetic polymorphism in FGFR4 rs351855 may be associated with the risk of HCC coupled with liver cirrhosis and may markedly increase the AFP level in Taiwanese patients with HCC. In addition, this is the first study that evaluated the risk factors associated with FGFR4 polymorphism variants in Taiwanese patients with HCC.

Original languageEnglish
Article numbere0122961
JournalPLoS One
Volume10
Issue number4
DOIs
Publication statusPublished - Apr 10 2015

Fingerprint

Receptor, Fibroblast Growth Factor, Type 4
liver cirrhosis
hepatoma
Polymorphism
Liver Cirrhosis
Liver
Hepatocellular Carcinoma
genetic polymorphism
Nucleotides
alpha-Fetoproteins
single nucleotide polymorphism
Single Nucleotide Polymorphism
Genotype
Tumors
genotype
fibroblast growth factor receptor 4
neoplasms
Genetic Polymorphisms
Genes
Neoplasms

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Sheu, M. J., Hsieh, M. J., Chiang, W. L., Yang, S. F., Lee, H. L., Lee, L. M., & Yeh, C. B. (2015). Fibroblast growth factor receptor 4 polymorphism is associated with liver cirrhosis in hepatocarcinoma. PLoS One, 10(4), [e0122961]. https://doi.org/10.1371/journal.pone.0122961

Fibroblast growth factor receptor 4 polymorphism is associated with liver cirrhosis in hepatocarcinoma. / Sheu, Ming Jen; Hsieh, Ming Ju; Chiang, Whei Ling; Yang, Shun Fa; Lee, Hsiang Lin; Lee, Liang Ming; Yeh, Chao Bin.

In: PLoS One, Vol. 10, No. 4, e0122961, 10.04.2015.

Research output: Contribution to journalArticle

Sheu, MJ, Hsieh, MJ, Chiang, WL, Yang, SF, Lee, HL, Lee, LM & Yeh, CB 2015, 'Fibroblast growth factor receptor 4 polymorphism is associated with liver cirrhosis in hepatocarcinoma', PLoS One, vol. 10, no. 4, e0122961. https://doi.org/10.1371/journal.pone.0122961
Sheu, Ming Jen ; Hsieh, Ming Ju ; Chiang, Whei Ling ; Yang, Shun Fa ; Lee, Hsiang Lin ; Lee, Liang Ming ; Yeh, Chao Bin. / Fibroblast growth factor receptor 4 polymorphism is associated with liver cirrhosis in hepatocarcinoma. In: PLoS One. 2015 ; Vol. 10, No. 4.
@article{93266e4f792a42f9a001a60f4cf8213a,
title = "Fibroblast growth factor receptor 4 polymorphism is associated with liver cirrhosis in hepatocarcinoma",
abstract = "Background: Fibroblast growth factor receptor 4 (FGFR4) polymorphisms are positively correlated with tumor progression in numerous malignant tumors. However, the association between FGFR4 genetic variants and the risk of hepatocellular carcinoma (HCC) has not yet been determined. In this study, we investigated the potential associations of FGFR4 single nucleotide polymorphisms (SNPs) with HCC susceptibility and its clinicopathological characteristics. Methodology/Principal Findings: Four SNPs in FGFR4 (rs1966265, rs351855, rs2011077, and rs7708357) were analyzed among 884 participants, including 595 controls and 289 patients with HCC. The samples were further analyzed to clarify the associations between these gene polymorphisms and the risk of HCC, and the impact of these SNPs on the susceptibility and clinicopathological characteristics of HCC. After adjusting for other covariants, HCC patients who carrying at least one A genotype (GA and AA) at rs351855 were observed to have a higher risk of liver cirrhosis compared with those carrying the wild-type genotype (GG) (OR: 2.113, 95{\%} CI: 1.188-3.831). Moreover, the patients with at least one A genotype were particularly showed a high level of alpha-fetoprotein (AFP). Conclusions: Our findings suggest that genetic polymorphism in FGFR4 rs351855 may be associated with the risk of HCC coupled with liver cirrhosis and may markedly increase the AFP level in Taiwanese patients with HCC. In addition, this is the first study that evaluated the risk factors associated with FGFR4 polymorphism variants in Taiwanese patients with HCC.",
author = "Sheu, {Ming Jen} and Hsieh, {Ming Ju} and Chiang, {Whei Ling} and Yang, {Shun Fa} and Lee, {Hsiang Lin} and Lee, {Liang Ming} and Yeh, {Chao Bin}",
year = "2015",
month = "4",
day = "10",
doi = "10.1371/journal.pone.0122961",
language = "English",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - Fibroblast growth factor receptor 4 polymorphism is associated with liver cirrhosis in hepatocarcinoma

AU - Sheu, Ming Jen

AU - Hsieh, Ming Ju

AU - Chiang, Whei Ling

AU - Yang, Shun Fa

AU - Lee, Hsiang Lin

AU - Lee, Liang Ming

AU - Yeh, Chao Bin

PY - 2015/4/10

Y1 - 2015/4/10

N2 - Background: Fibroblast growth factor receptor 4 (FGFR4) polymorphisms are positively correlated with tumor progression in numerous malignant tumors. However, the association between FGFR4 genetic variants and the risk of hepatocellular carcinoma (HCC) has not yet been determined. In this study, we investigated the potential associations of FGFR4 single nucleotide polymorphisms (SNPs) with HCC susceptibility and its clinicopathological characteristics. Methodology/Principal Findings: Four SNPs in FGFR4 (rs1966265, rs351855, rs2011077, and rs7708357) were analyzed among 884 participants, including 595 controls and 289 patients with HCC. The samples were further analyzed to clarify the associations between these gene polymorphisms and the risk of HCC, and the impact of these SNPs on the susceptibility and clinicopathological characteristics of HCC. After adjusting for other covariants, HCC patients who carrying at least one A genotype (GA and AA) at rs351855 were observed to have a higher risk of liver cirrhosis compared with those carrying the wild-type genotype (GG) (OR: 2.113, 95% CI: 1.188-3.831). Moreover, the patients with at least one A genotype were particularly showed a high level of alpha-fetoprotein (AFP). Conclusions: Our findings suggest that genetic polymorphism in FGFR4 rs351855 may be associated with the risk of HCC coupled with liver cirrhosis and may markedly increase the AFP level in Taiwanese patients with HCC. In addition, this is the first study that evaluated the risk factors associated with FGFR4 polymorphism variants in Taiwanese patients with HCC.

AB - Background: Fibroblast growth factor receptor 4 (FGFR4) polymorphisms are positively correlated with tumor progression in numerous malignant tumors. However, the association between FGFR4 genetic variants and the risk of hepatocellular carcinoma (HCC) has not yet been determined. In this study, we investigated the potential associations of FGFR4 single nucleotide polymorphisms (SNPs) with HCC susceptibility and its clinicopathological characteristics. Methodology/Principal Findings: Four SNPs in FGFR4 (rs1966265, rs351855, rs2011077, and rs7708357) were analyzed among 884 participants, including 595 controls and 289 patients with HCC. The samples were further analyzed to clarify the associations between these gene polymorphisms and the risk of HCC, and the impact of these SNPs on the susceptibility and clinicopathological characteristics of HCC. After adjusting for other covariants, HCC patients who carrying at least one A genotype (GA and AA) at rs351855 were observed to have a higher risk of liver cirrhosis compared with those carrying the wild-type genotype (GG) (OR: 2.113, 95% CI: 1.188-3.831). Moreover, the patients with at least one A genotype were particularly showed a high level of alpha-fetoprotein (AFP). Conclusions: Our findings suggest that genetic polymorphism in FGFR4 rs351855 may be associated with the risk of HCC coupled with liver cirrhosis and may markedly increase the AFP level in Taiwanese patients with HCC. In addition, this is the first study that evaluated the risk factors associated with FGFR4 polymorphism variants in Taiwanese patients with HCC.

UR - http://www.scopus.com/inward/record.url?scp=84928889791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928889791&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0122961

DO - 10.1371/journal.pone.0122961

M3 - Article

C2 - 25860955

AN - SCOPUS:84928889791

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e0122961

ER -